Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03589729
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
- Conditions
- Interventions
- Drug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-mercaptopurine.Drug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: KaryotypingDrug: ChidamideDiagnostic Test: PET-CT scan
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT03564704
- Locations
- 🇨🇳
Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
- Conditions
- Interventions
- Drug: ChidamideDrug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-MercaptopurineDrug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: Karyotyping
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 70
- Registration Number
- NCT03553238
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
- Conditions
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Registration Number
- NCT03444649
- Locations
- 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
- Conditions
- Interventions
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2020-02-05
- Target Recruit Count
- 4000
- Registration Number
- NCT03390387
- Locations
- 🇷🇺
Morozov Children's Municipal Clinical Hospital, Moscow, Russian Federation
🇦🇲prof. R.O.Eolyan Hematology Center, Ereván, Armenia
🇷🇺Transbaikal Regional Oncology Dispensary, Chita, Russian Federation
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 53
- Registration Number
- NCT03330821
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT03250338
- Locations
- 🇺🇸
Kansas University, Kansas City, Kansas, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 75
- Registration Number
- NCT03226418
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT03214562
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
- Conditions
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT03194932
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Lucille Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.